🧬 CH50 (Total Complement Activity) Test
🧬 CH50 (Total Complement Activity) Test — Purpose, LIA Method, Reference Range, and Clinical Significance
The CH50 test is one of the most important laboratory tools for evaluating the classical complement pathway. Because complement proteins play a key role in immunity, inflammation, and host defense, measuring their functional activity is essential in many clinical settings.
Below is a comprehensive summary of what the CH50 test measures, how it works, and how to interpret the results.
1. What Is the CH50 Test?
CH50 (50% hemolytic complement activity) measures how effectively the classical complement pathway is activated.
- Reflects functional activity of complement proteins C1 through C9
- Serves as a global indicator of classical pathway function
- Helps detect complement consumption, immune activation, or congenital complement deficiencies
Because many diseases alter complement levels, CH50 is frequently used in autoimmune, infectious, and inflammatory disorders.
2. Purpose of the CH50 Test
1) Autoimmune Diseases (especially SLE)
- Evaluates complement consumption
- Helps assess disease activity
- During SLE flare: CH50 ↓, C3 ↓, C4 ↓
2) Diagnosis of Congenital Complement Deficiencies
- Low or absent CH50 suggests deficiency of C1, C2, C4 or the terminal components (C5–C9)
- Essential in patients with recurrent Neisseria infections (e.g., meningococcal disease)
3) Evaluation of Acute and Chronic Infection
- Complement may increase as an acute-phase reactant
- Severe infections may also cause complement consumption
4) General Immunologic Evaluation
- Immune complex–related diseases alter complement activity
- Autoantibodies may activate or consume complement proteins
3. Test Method — Liposome Immunoassay (LIA)
Modern CH50 analysis commonly uses the Liposome Immunoassay (LIA) method.
Compared with older hemolytic assays, LIA offers better reproducibility and automation.
● Principle of LIA
Liposomes containing a dye are designed to rupture when the classical complement pathway is activated.
- Patient serum is incubated with complement-reactive liposomes
- Activated complement lyses the liposomes
- Dye is released
- The intensity of the released signal (absorbance/fluorescence)
→ correlates directly with complement activity
● Advantages of LIA
- Automated and reproducible
- Faster than traditional hemolytic assays
- Less variability from hemolysis or manual technique
- Ideal for clinical monitoring
4. Reference Range
Reference values depend on the reagent and platform used. Typical ranges:
CH50: 30–60 U/mL
(or 100–150 CH50 units, depending on manufacturer)
Always interpret CH50 using the reference range provided by the testing laboratory.
5. Clinical Significance
(1) Causes of Decreased CH50
1) Systemic Lupus Erythematosus (SLE)
- Complement consumption during disease flare
- CH50, C3, C4 all decrease
2) Congenital Complement Deficiencies
- C1, C2, C4 deficiency: CH50 nearly absent
- C5–C9 deficiency: impaired MAC formation → recurrent Neisseria infections
3) Immune Complex Diseases
- Vasculitis
- Glomerulonephritis
- Cryoglobulinemia
Immune complexes activate classical pathway → CH50 decreases
4) Severe Liver Disease
- The liver synthesizes most complement proteins
- CH50 decreases with advanced hepatic dysfunction
(2) Causes of Increased CH50
1) Acute-Phase Reactions
- Infections, inflammation, trauma
- Complement proteins act as acute-phase reactants
2) Malignancy
- Certain solid tumors and lymphoproliferative disorders increase complement production
3) Chronic Inflammatory Diseases
- Rheumatoid arthritis
- Chronic infections
4) Corticosteroid Therapy
- Steroids can increase complement synthesis
6. Important Notes for Interpretation
⭐ Always interpret CH50 together with C3 and C4
- C3 ↓, C4 normal → likely alternative pathway issue
- C3 ↓, C4 ↓, CH50 ↓ → consumption (e.g., SLE flare or immune-complex disease)
⭐ Combine with AH50 (alternative pathway activity)
- Helps differentiate classical vs. alternative pathway defects
⭐ Sample quality matters
- Hemolyzed samples activate complement in vitro → may falsely lower CH50
⭐ Use serum, not plasma
- EDTA or heparin inhibits complement activation → invalid results
7. Summary Table
| Result | Possible Causes |
|---|---|
| CH50 Decreased | SLE, complement deficiencies (C1–C9), immune-complex diseases, severe liver disease, complement consumption |
| CH50 Increased | Acute-phase reaction, chronic inflammation, malignancy, steroid effect |
8. References
- Walport MJ. Complement. Part 1. New England Journal of Medicine.
- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th ed.
- Sjöholm AG. Complement assays in clinical immunology. Clin Diagn Lab Immunol.
- Mayo Clinic Laboratories – CH50 test catalog
- ARUP Laboratories – Total Complement Activity (CH50) assay
- Manufacturer’s guidelines for LIA-based CH50 reagents